Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option PR Newswire SAN DIEGO, Oct. 25, 2013 SAN DIEGO, Oct. 25, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE...
Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain PR Newswire SAN DIEGO, Oct. 10, 2013 SAN DIEGO, Oct. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics...
Sorrento Therapeutics Announces a Presentation on Cynviloq™ at the AACR Conference on Advances in Ovarian Cancer Research: From Concept to Clinic PR Newswire SAN DIEGO, Sept. 16, 2013 SAN DIEGO...
Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy PR Newswire SAN DIEGO, Sept. 10, 2013 SAN...
Sorrento Therapeutics Completes IgDraSol Merger PR Newswire SAN DIEGO, Sept. 10, 2013 SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced...
Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway Official Minutes from End-of-Phase 2 FDA Meeting Provide Clarity on Next...
Sorrento Therapeutics Announces Reverse Split of Common Stock PR Newswire SAN DIEGO, Aug. 1, 2013 SAN DIEGO, Aug. 1, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento...
Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine Conference in Sydney, Australia PR Newswire SAN DIEGO...
Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market PR Newswire MOUNTAIN VIEW, California, June 6, 2013 MOUNTAIN...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0006 | 28.5714285714 | 0.0021 | 0.004 | 0.0006 | 409828 | 0.00364569 | CS |
| 4 | 0.0021 | 350 | 0.0006 | 0.01 | 0.0006 | 267464 | 0.00339916 | CS |
| 12 | 0.0022 | 440 | 0.0005 | 0.0925 | 0.0005 | 188046 | 0.00517284 | CS |
| 26 | -0.0108 | -80 | 0.0135 | 0.0925 | 0.0002 | 145677 | 0.00753052 | CS |
| 52 | -0.0133 | -83.125 | 0.016 | 0.0925 | 0.0001 | 155986 | 0.01043147 | CS |
| 156 | -7.8573 | -99.965648855 | 7.86 | 7.86 | 0.0001 | 150607 | 0.01043147 | CS |
| 260 | -7.8573 | -99.965648855 | 7.86 | 7.86 | 0.0001 | 147554 | 0.01043147 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
